
    
      65 patients with advanced or metastatic adenocarcinoma of the oesophagogastric junction and
      stomach will be treated with 20mg/m2 Cabazitaxel for a maximum of 6 cycles. Main objective of
      the study is the Disease Control Rate (DCR) with Cabazitaxel.
    
  